- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
MindWalk Holdings Corp.(HYFT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for HYFT
11/13/2026: HYFT (1-star) is currently NOT-A-BUY. Pass it for now.
MindWalk Holdings Corp. is a micro-cap bio-native AI and life sciences company that leverages its proprietary HYFT and LensAI platforms alongside full-stack wet-lab capabilities to accelerate antibody discovery. The company's core strengths lie in its differentiated computational language models and established enterprise partnerships with major global pharmaceutical clients. Its primary growth story centers on capitalizing on the increasing adoption of generative AI within drug development pipelines. However, key risks include ongoing net operating losses, micro-cap share volatility, and intense competition in the TechBio sector. The stock suits risk-tolerant growth or momentum investors seeking exposure to computational biology, requiring close monitoring of partnership contract wins and cash-burn metrics.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | While operating in a high-growth TechBio sector, its micro-cap size and early-stage scaling introduce execution uncertainties. |
| Momentum investor | Strong fit while signal remains positive | The stock can experience sharp volume-driven rallies upon major commercial partnership or platform milestone announcements. |
| Value investor | Weak fit | The company lacks current profitability and positive earnings multiples, making it unsuitable for traditional value metrics. |
| Dividend investor | Weak fit | MindWalk does not pay dividends, directing all available capital into technology development and operations. |
| Low-risk investor | Weak fit | High share price volatility, micro-cap liquidity profile, and negative net income create substantial risk exposure. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock exhibits wide price swings and high beta, typical of micro-cap technology equities. |
| Valuation risk | Medium / high | Valuation is heavily dependent on future software adoption and speculative platform growth projections. |
| Competition risk (AI platform competition) | High | The company competes with heavily funded AI drug discovery firms and internal pharmaceutical R&D initiatives. |
| Business quality | Medium | Proprietary technology provides strong scientific differentiation, but ongoing losses weigh on near-term financial quality. |
| Dividend income | Low / none | No payouts are distributed to investors, eliminating dividend income generation. |
| Execution risk | High | Success relies heavily on scaling platform contracts and translating computational insights into commercial milestones. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 47.10M USD | Price to earnings Ratio - | 1Y Target Price 4.33 |
Price to earnings Ratio - | 1Y Target Price 4.33 | ||
Volume (30-day avg) 326.0K shares | Beta 0.78 | 52 Weeks Range 0.91 - 2.99 | Updated Date 11/15/2026 |
52 Weeks Range 0.91 - 2.99 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.26 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 105.12% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| AI Platforms and Software Licensing | Licensing proprietary tools like LensAI and HYFT to pharmaceutical partners for data analysis and target discovery. | Generates high-margin recurring or project-based technology access fees from drug developers. |
| Contract Research Services | Providing custom wet-lab antibody discovery, characterization, and validation services. | Serves as a reliable baseline service revenue stream while closing the loop for AI-discovered candidates. |
| Geography (North America & International) | Service delivery and licensing contracts spanning the United States, Europe, Canada, and Australia. | Diversifies commercial exposure across major global biotech and pharma hubs. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 46.10M | Price to Sales(TTM) 2.9 |
Enterprise Value 46.10M | Price to Sales(TTM) 2.9 | ||
Enterprise Value to Revenue 4.05 | Enterprise Value to EBITDA -4.68 | Shares Outstanding 47.57M | Shares Floating 42.69M |
Shares Outstanding 47.57M | Shares Floating 42.69M | ||
Percent Insiders 9.25 | Percent Institutions 9.08 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

